$10.38
11.40% today
Nasdaq, Apr 01, 07:19 pm CET
ISIN
US64049K1043
Symbol
NGNE
Sector
Industry

Neoleukin Therapeutics Inc Stock price

$11.71
-5.98 33.80% 1M
-30.25 72.09% 6M
-11.15 48.78% YTD
-35.07 74.97% 1Y
-25.89 68.86% 3Y
-215.89 94.86% 5Y
-152.69 92.88% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-2.81 19.35%
ISIN
US64049K1043
Symbol
NGNE
Sector
Industry

Key metrics

Market capitalization $174.83m
Enterprise Value $-125.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.79
EV/Sales (TTM) EV/Sales -134.57
P/S ratio (TTM) P/S ratio 187.99
P/B ratio (TTM) P/B ratio 0.56
Revenue (TTM) Revenue $930.00k
EBIT (operating result TTM) EBIT $-82.61m
Free Cash Flow (TTM) Free Cash Flow $-69.96m
Cash position $312.41m
EPS (TTM) EPS $-4.60
P/E forward negative
Short interest 16.17%
Show more

Is Neoleukin Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Neoleukin Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Neoleukin Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Neoleukin Therapeutics Inc forecast:

Buy
100%

Financial data from Neoleukin Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.93 0.93
-
100%
- Direct Costs 3.25 3.25
0% 0%
349%
-2.33 -2.33
29% 29%
-251%
- Selling and Administrative Expenses 16 16
105% 105%
1,732%
- Research and Development Expense 61 61
43% 43%
6,551%
-79 -79
48% 48%
-8,532%
- Depreciation and Amortization 3.25 3.25
0% 0%
349%
EBIT (Operating Income) EBIT -83 -83
45% 45%
-8,882%
Net Profit -75 -75
107% 107%
-8,080%

In millions USD.

Don't miss a Thing! We will send you all news about Neoleukin Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neoleukin Therapeutics Inc Stock News

Neutral
Business Wire
8 days ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates. “We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Ret...

Company Profile

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Head office United States
CEO Rachel McMinn
Employees 107
Founded 2018
Website www.neurogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today